Tower Research Capital (TRC)’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Tower Research Capital (TRC)’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-647	Closed	-$7K	–	6602
2023 Q1	$7K	Sell	647 -10	-2%	-$101	﹤0.01%	4807
2022 Q4	$7K	Sell	657 -330	-33%	-$3.29K	﹤0.01%	4663
2022 Q3	$10K	Sell	987 -2	-0.2%	-$20	﹤0.01%	4615
2022 Q2	$10K	Buy	+989	New	+$9.78K	﹤0.01%	4518
2021 Q2	–	Sell	-1	Closed	–	–	6032
2021 Q1	$0	Buy	+1	New	+$10	﹤0.01%	5871

Tower Research Capital (TRC)'s EUCR Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2023, closing a stake of 647 shares — an estimated $7K sold.

Tower Research Capital (TRC) first reported a position in EUCR in Q1 2021 and held it in 5 quarters. The position peaked at $10K in Q3 2022. 0 funds tracked by Wall St. Rank hold EUCR as of Q2 2023.

Tower Research Capital (TRC) reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 647 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2023, an estimated $7K.
Tower Research Capital (TRC) first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 5 quarters.
Tower Research Capital (TRC)'s Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $10K in Q3 2022.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.